智通财经APP获悉,周四,美国消费者团体和两个大型工会敦促美国联邦贸易委员会(FTC)阻止诺和诺德(NVO.US)股东Novo Holdings收购合同药品制造商Catalent Inc.(CTLT.US),称该交易威胁到减肥药和尖端基因疗法领域的竞争。 美国公共利益研究小组(U.S. Public Interest Research Group)、服务业雇员国际联盟(SEIU)等机构在致FTC的 ...
Consumer groups, labor unions, and Senator Elizabeth Warren have urged the FTC to block Novo Holdings from acquiring Catalent. Concerns center on competition in weight loss drugs and gene therapies.